ALLERGY THERAPEUTICS (HOLDINGS) LIMITED

1. ALLERGY THERAPEUTICS (HOLDINGS) LIMITED 1998-06-26 → present
2. HAMSARD ONE THOUSAND AND EIGHTY SEVEN LIMITED 1998-05-18 → 1998-06-26

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

BDO LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“In auditing the financial statements, we have concluded that the Directors' use of the going concern basis of accounting is appropriate. We have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company's ability to continue as a going concern for at least twelve months from when the financial statements are authorised for issue.”

Group structure

1. ALLERGY THERAPEUTICS (HOLDINGS) LIMITED · parent
   1. Allergy Therapeutics (UK) Ltd 100% · UK · Manufacture and sale of pharmaceutical products
   2. Bencard Allergie GmbH 100% · Germany · Sale of pharmaceutical products
   3. Bencard Allergie (Austria) GmbH 100% · Austria · Sale of pharmaceutical products
   4. Allergy Therapeutics Italia s.r.l. 100% · Italy · Sale of pharmaceutical products
   5. Allergy Therapeutics Iberica S.L. 100% · Spain · Sale of pharmaceutical products
   6. Bencard A.G. 100% · Switzerland · Sale of pharmaceutical products
   7. Allergy Therapeutics Netherlands BV 100% · Netherlands · Sale of pharmaceutical products
   8. Allergy Therapeutics Argentina S.A. 95% · Argentina · In liquidation

Significant events

• “Between the balance sheet date and 20 October 2025, the Group drew down £12.5m under the Amended Shareholder Facility and issued further warrants... On 29 October 2025, the Parent Company received exercise notices from the Shareholder Lenders in respect of the 1,375,000,000 warrants, which would generate aggregate proceeds of £55m on exercise... all financial indebtedness owed by the Group to the Shareholder Lenders under the Amended Shareholder Facility, has effectively been repaid.”
• “1,375,000,000 new Ordinary Shares were issued to the Shareholder Lenders following exercise of their warrants...”
• “The Lenders have agreed to provide a new £50m unsecured loan facility (the "Renewed Shareholder Facility") on an uncommitted basis. The Renewed Shareholder Facility is available to draw down from 29 October 2025 until 15 July 2030, with interest payable at 12 per cent. per annum and a repayment date of 15 October 2030.”
• “Post year end it was announced to the London Stock Exchange that the Group is exploring a potential dual primary listing on the Hong Kong Stock Exchange... to expand Allergy Therapeutics' presence in Asia and to strengthen our position as a global leader in allergy immunotherapy.”
• “On 20 February 2026, the Group entered into an amendment to the secured senior loan facility... under which a new £40m senior secured facility (the "2026 Hayfin Facility) was made available to the Group. The Group immediately drew down the full £40m made available under 2026 Hayfin Facility.”
• “As part of the financing arrangements related to the 2026 Hayfin Facility, the Group Parent Company also granted Hayfin rights to subscribe for 59,546,848 new Ordinary Shares at a subscription price of 0.1 pence per Ordinary Share... resulting in the issue of 58,955,876 new Ordinary Shares to Hayfin, fully paid.”
• “As part of the 2024 Hayfin Facility the Group Parent Company had previously issued a total of 133,458,226 warrants to Hayfin... resulting in the issue of 132,133,723 new Ordinary Shares to Hayfin, fully paid.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

4

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  —

  Not reported

• Cash

  —

  Not reported

• Net assets

  +4.6%

  £11,077,000 → £11,586,000

• Employees

  —

  Not reported

• Operating profit

  -119.4%

  £2,674,000 → -£518,000

• Profit before tax

  -113.5%

  £2,666,000 → -£361,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers